TMCnet News
Research and Markets: Global Cardiovascular Drug Delivery Report 2014-2023 - Technologies, Markets and Companies Analysis [Updated]DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/x5w9dj/cardiovascular) has announced the addition of Jain PharmaBiotech's new report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" to their offering. Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions. A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries. Fifteen companies are involved in drug-eluting stents. New cell-based therapeutic strategies are being developed in response to the shortcomings of available treatments for heart disease. Potential repair by cell grafting or mobilizing endogenos cells holds particular attraction in heart disease, where the meager capacity for cardiomyocyte proliferation likely contributes to the irreversibility of heart failure. Cell therapy approaches include attempts to reinitiate cardiomyocyte proliferation in the adult, conversion of fibroblasts to contractile myocytes, conversion of bone marrow stem cells into cardiomyocytes, and transplantation of myocytes or other cells into injured myocardium. Advances in molecular pathophysiology of cardiovascular diseases have brought gene therapy within the realm of possibility as a novel approach to treatment of these diseases. It is hoped that gene therapy will be less expensive and affordable because the techniques involved are simpler than those involved in cardiac bypass surgery, heart transplantation and stent implantation. Gene therapy would be a more physiologic approach to deliver vasoprotective molecules to the site of vascular lesion. Gene therapy is not only a sophisticated method of drug delivery; it may at time need drug delivery devices such as catheters for transfer of genes to various parts of the cardiovascular system. The cardiovascular drug delivery markets are estimated for the years 2013 to 2023 on the basis of epidemiology and total markets for cardiovascular therapeutics. The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified. Key Topics Covered: Executive Summary 1. Cardiovascular Diseases 2. Methods for Drug Delivery to the Cardiovascular System 3. Cell Therapy for Cardiovascular Disorders 4. Gene Therapy for Cardiovascular Disorders 5. Drug-Eluting Stents 6. Markets for Cardiovascular Drug Delivery 7. Companies involved in Cardiovascular Drug Delivery 8. References For more information visit http://www.researchandmarkets.com/research/x5w9dj/cardiovascular Source (News - Alert): Jain PharmaBiotech |
